MCL Clinical Trials

1230 trials from ClinicalTrials.gov. Recruiting trials shown first.

Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)

NCT02631044·PHASE1·Juno Therapeutics, a Subsidiary of Celgene·387 enrolled

JCAR017 (lisocabtagene maraleucel) single-dose scheduleJCAR017 (lisocabtagene maraleucel) 2-dose schedule

EDOCH Alternating With DHAP for New Diagnosed Younger MCL

NCT02858804·PHASE4·Institute of Hematology & Blood Diseases Hospital, China·55 enrolled

EtoposideDoxorubicinDexamethasoneVincristineCyclophosphamide+5 more

Pembrolizumab in Patients Failing to Respond to or Relapsing After CAR T Cell Therapy for Relapsed or Refractory Lymphomas

NCT02650999·PHASE1 / PHASE2·Abramson Cancer Center at Penn Medicine·12 enrolled

Study of Loratadine for Pegfilgrastim Induced Bone Pain in Patients With Aggressive Lymphoma

NCT02392039·EARLY_PHASE1·M.D. Anderson Cancer Center·1 enrolled

PegfilgrastimLoratadinePlaceboQuestionnaires

Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma

NCT02633137·PHASE2·Memorial Sloan Kettering Cancer Center·49 enrolled

LenalidomideR-CHOPhigh-dose cytarabine (HIDAC)

Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma

NCT02652910·PHASE1 / PHASE2·Xinqiao Hospital of Chongqing·20 enrolled

CD19.CAR-T cells

Long-Term Followup and/or Thalidomide Maintenance Therapy for Patients Enrolled on Clinical Trial 20030165

NCT02507336·PHASE2·University of Miami·2 enrolled

Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL

NCT02603445·PHASE1·Novartis Pharmaceuticals·20 enrolled

BCL201Idelalisib

Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2)

NCT02601313·PHASE2·Kite, A Gilead Company·105 enrolled

brexucabtagene autoleucelCyclophosphamideFludarabineAxicabtagene Ciloleucel

Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT02420795·PHASE1 / PHASE2·M.D. Anderson Cancer Center·16 enrolled

Akt/ERK Inhibitor ONC201Laboratory Biomarker AnalysisPharmacological Study

CD34+ Selected ASCT for Aggressive Lymphomas

NCT02646098·PHASE2·Insel Gruppe AG, University Hospital Bern·64 enrolled

CD34+ cell selection

A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients

NCT02558816·PHASE1 / PHASE2·Nantes University Hospital·48 enrolled

Ibrutinib + GA101 +GDC-0199

An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma

NCT02413489·PHASE2·Janssen Research & Development, LLC·36 enrolled

Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma

NCT02356458·PHASE1 / PHASE2·Swiss Cancer Institute·58 enrolled

Ibrutinibbortezomib

Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL)

NCT02455297·PHASE2·Bayer·4 enrolled

Copanlisib (BAY80-6946)

Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

NCT02489123·PHASE2·University of Washington·8 enrolled

EnzalutamideLaboratory Biomarker Analysis

ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM)

NCT02471391·PHASE2·Peter MacCallum Cancer Centre, Australia·37 enrolled

ABT-199Ibrutinib

A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies

NCT02454270·PHASE1·Janssen Research & Development, LLC·59 enrolled

Part 1 (Dose Escalation): DuvortuxizumabPart 2 (Dose Expansion): Duvortuxizumab

Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma

NCT02303392·PHASE1·Jennifer Woyach·34 enrolled

SelinexorIbrutinibPharmacological StudyLaboratory Biomarker Analysis

Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy

NCT02381080·PHASE1·Janssen Research & Development, LLC·26 enrolled

IbrutinibErythromycinVoriconazole

A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors

NCT02440685·PHASE1 / PHASE2·Asana BioSciences·51 enrolled

ASN002 Dose EscalationASN002 RD

Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma

NCT02269085·PHASE1·M.D. Anderson Cancer Center·8 enrolled

IbrutinibCarfilzomibPhone Calls

A Trial Comparing the Two High-dose Chemotherapies BeEAM and BEAM Given Before Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial)

NCT02278796·PHASE2·Insel Gruppe AG, University Hospital Bern·108 enrolled

Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib Treatment

NCT02341781·Celgene·30 enrolled

Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL

NCT02419560·PHASE1·Craig Portell, MD·37 enrolled

ABT-199 and Ibrutinib Combination

A Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma

NCT02460276·PHASE2·Lund University Hospital·50 enrolled

LenalidomideIbrutinibRituximab

Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation

NCT02285244·PHASE2·James Blachly

sotrastaurin acetatepharmacological studylaboratory biomarker analysis

Phase II of Efficacy and Toxicity of Maintenance Sub. Rituximab After Induction in Relapsed MCL and Non-eligible HSCT

NCT02267915·PHASE2·Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea·36 enrolled

subcutaneous Rituximab

ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies

NCT02362035·PHASE1 / PHASE2·Acerta Pharma BV·161 enrolled

AcalabrutinibPembrolizumab

Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma

NCT01609816·PHASE1·Barbara Ann Karmanos Cancer Institute·8 enrolled

← PreviousPage 15 of 41Next →